Loading
A phase 3 trial of Rilvegostomig, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC is a phase 3 interventional study registered as NCT06627647 by AstraZeneca, with 1160 participants planned, started 2024-11-27 and due to reach its primary completion in 2030-11-18. Interventions recorded: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, AstraZeneca, Carboplatin, Small-cell lung cancer.
Shares Rilvegostomig, Pemetrexed, AstraZeneca, Cisplatin.
Shares Pemetrexed, AstraZeneca, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, AstraZeneca, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/